Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Beam Therapeutics Inc(BEAM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BEAM
11/09/2026: BEAM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Beam Therapeutics is a clinical-stage biotechnology company developing precision genetic medicines using its proprietary base editing platform. The company is known for its advanced genomic technology which aims to address severe diseases with greater precision than traditional methods. Its primary investment story centers on the success of its lead programs like BEAM-101 in clinical trials. However, Beam faces significant risks including clinical execution, intense competition in the gene-editing space, and the high cash burn associated with R&D. The stock may best suit growth-oriented investors who are comfortable with high-risk, high-reward biotech assets and should closely monitor clinical trial updates and regulatory milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers exposure to high-growth, innovative gene-editing technology in a pre-commercial stage. |
| Momentum investor | Mixed fit | Momentum is highly conditional on positive clinical trial data announcements which can trigger significant volatility. |
| Value investor | Weak fit | The company lacks current earnings or traditional valuation metrics, making it unsuitable for value-focused strategies. |
| Dividend investor | Weak fit | Beam Therapeutics does not pay dividends and focuses all capital on long-term growth and research. |
| Low-risk investor | Weak fit | The company faces high clinical, regulatory, and financial risks typical of an early-stage biotechnology firm. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stock prices often swing dramatically based on clinical trial results and regulatory updates. |
| Valuation risk | High | Valuations are speculative and rely heavily on the long-term success of early-stage therapeutic candidates. |
| Competition risk (Gene Editing) | Medium / high | Rapid technological advancements by peers could render specific approaches less competitive. |
| Business quality | Medium | While the technology is advanced, the company lacks a commercial product foundation or revenue consistency. |
| Dividend income | Low / none | There is no expectation of dividend income for the foreseeable future. |
| Execution risk | High | Success depends entirely on the complex clinical validation and regulatory approval of unproven genetic medicines. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -54.66% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.73B USD | Price to earnings Ratio - | 1Y Target Price 49.62 |
Price to earnings Ratio - | 1Y Target Price 49.62 | ||
Volume (30-day avg) 1.9M shares | Beta 2.22 | 52 Weeks Range 20.23 - 38.26 | Updated Date 11/08/2026 |
52 Weeks Range 20.23 - 38.26 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biopharmaceutical R&D | Collaborations, licensing agreements, and potential future product sales from clinical-stage pipelines. | The company currently spends more than it earns, aiming to generate revenue from future successful drug approvals and partnerships. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.93B | Price to Sales(TTM) 18.64 |
Enterprise Value 1.93B | Price to Sales(TTM) 18.64 | ||
Enterprise Value to Revenue 13.18 | Enterprise Value to EBITDA -7.03 | Shares Outstanding 103.50M | Shares Floating 88.07M |
Shares Outstanding 103.50M | Shares Floating 88.07M | ||
Percent Insiders 1.2 | Percent Institutions 107.38 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.